Clinical study results

In mCSPC, ERLEADA® gave certain men a chance to live longer.

In men with prostate cancer that HAS SPREAD to other parts of the body and STILL responds to a medical or surgical treatment that lowers testosterone

in a clinical study, ERLEADA® +ADT reduced the risk of death by 33% vs men taking placebo + ADT

ERLEADA® gave certain men more time without their cancer progressing

in a clinical study, ERLEADA® +ADT reduced the risk of prostate cancer progressing by 52% vs men taking placebo + ADT

The clinical study for men with mCSPC also evaluated this additional measure:

ERLEADA® gave certain men more time without starting chemotherapy

in a clinical study, ERLEADA® + ADT reduced the risk of beginning chemotherapy by 61% vs men taking placebo + ADT

ERLEADA® + ADT was compared with placebo + ADT in a clinical study of 1052 men with metastatic castration-sensitive prostate cancer (mCSPC).

In this study, patients received either ERLEADA® at a dose of 240 mg once daily or placebo. All patients in the study received ADT.

*Pronounced “pluh-see-bow”: a pill that looks like “real” medicine but contains nothing to affect health.

Androgen deprivation therapy includes medical or surgical treatment that lowers testosterone.

Progression was defined as the length of time patients lived without their disease spreading further as measured by imaging studies or dying.

In nmCRPC, ERLEADA® helped delay the spread of prostate cancer.

In men with prostate cancer that HAS NOT SPREAD to other parts of the body and NO LONGER responds to a medical or surgical treatment that lowers testosterone

In a clinical study, ERLEADA® + ADT* delayed the spread of cancer to other parts of the body or death by 2 years (24.3 months) compared with placebo + ADT

MEDIAN MONTHS: Median number of months living without metastasis.

 

The clinical study for men with nmCRPC also evaluated time to metastasis, progression-free survival, and overall survival.

Time to Metastasis

Length of time from when patients began study to when prostate cancer had spread to other parts of the body (based on imaging).

MEDIAN MONTHS

40.5
WITH
ERLEADA®
+ ADT

VS

16.6
WITH
PLACEBO
+ ADT

Progression-Free Survival

Length of time patients lived without their prostate cancer spreading to local or distant parts of the body or death.

40.5
WITH
ERLEADA®
+ ADT

VS

14.7
WITH
PLACEBO
+ ADT

Overall Survival

Length of time patients lived after starting treatment as part of the study.

This study is ongoing and continues to evaluate overall survival.

ERLEADA® + ADT was compared with placebo + ADT in a clinical study of 1207 men with non-metastatic castration-resistant prostate cancer (nmCRPC).

In this study, patients received either ERLEADA® at a dose of 240 mg once daily or placebo. All patients in the study received ADT.

*Androgen deprivation therapy includes medical or surgical treatment that lowers testosterone.

Pronounced “pluh-see-bow”: a pill that looks like “real” medicine but contains nothing to affect health.

Median means that for 50% of the patients, living without metastasis was longer than 40.5 months, and for 50% of the patients, it was shorter than 40.5 months.

Helpful Information and Resources

Patient and doctor during office visit discussing ERLEADA® (apalutamide)

Doctor Discussion Guide

Contains questions to help start a conversation with your doctor.

Download

Boxing coach with prostate cancer from ERLEADA® (apalutamide) commercial ringside

ERLEADA® Patient Brochure

Contains important information about mCSPC, nmCRPC, and ERLEADA®.

Download